

# Renewed Priorities for a New Era at IDSA

*2024 Year in Review*



# IDSA Key Priorities: 2020-2024

ID Workforce

Fair Compensation

Progress on AMR

Practice Guidelines



# IDSA Key Priorities: 2021-2024

ID Workforce

Fair Compensation

Progress on AMR

Practice Guidelines

***Pandemic Preparedness***





“The infectious diseases workforce is a  
**robust, diverse and innovative  
community** that advances scientific  
discovery and protects and heals the world.”

IDSA Workforce Development Vision  
August 2023



# Physician Compensation

Negotiation Tools and Resources

Regional In-Person Sessions

Compensation that Reflects ID Value



[idsociety.org/compensation](https://idsociety.org/compensation)





# Secure Our Seat at the Table

## Adequately Valuing ID Physician Services

- HCPCS add-on code
- Outpatient complexity code

## Bio-Preparedness Workforce Pilot Program

## PASTEUR Act



Get Involved:  
[idsociety.org/MAP](https://idsociety.org/MAP)



# Guidelines


## Current Priorities



Increase production of high-quality guidelines and guideline updates



Expand portfolio with additional guidance products



Improve guideline dissemination and implementation

## 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Complicated Intra-abdominal Infections: Risk Assessment, Diagnostic Imaging, and Microbiological Evaluation in Adults, Children, and Pregnant People

Robert A. Bonomo,<sup>1,2,3,4</sup> Anthony W. Chow,<sup>5</sup> Morven S. Edwards,<sup>6</sup> Romney Humphries,<sup>7</sup> Pranita D. Tamma,<sup>8</sup> Fredrick M. Abrahamian,<sup>9,10</sup> Mary Bessesen,<sup>11,12</sup> E. Patchen Dellinger,<sup>13</sup> Ellie Goldstein,<sup>14</sup> Mary K. Hayden,<sup>15</sup> Keith S. Kaye,<sup>16</sup> Brian A. Potoski,<sup>17</sup> Jesús Rodríguez-Baño,<sup>18</sup> Robert Sawyer,<sup>19</sup> Marion Skalweit,<sup>20</sup> David R. Snyderman,<sup>21</sup> Sarah Pahlke,<sup>22</sup> Katelyn Donnelly,<sup>23</sup> and Jennifer Loveless<sup>24</sup>

<sup>1</sup>Medical Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA; <sup>2</sup>Clinical Scientist Investigator, Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA; <sup>3</sup>Departments of Medicine, Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Pathology and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; <sup>4</sup>CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES) Cleveland, Ohio, USA; <sup>5</sup>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; <sup>6</sup>Division of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA; <sup>7</sup>Division of Laboratory Medicine, Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA; <sup>8</sup>Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; <sup>9</sup>Department of Emergency Medicine, Olive View-University of California Los Angeles (UCLA) Medical Center, Sylmar, California, USA; <sup>10</sup>David Geffen School of Medicine at UCLA, Los Angeles, California, USA; <sup>11</sup>Department of Medicine, Veterans Affairs Eastern Colorado Health Care, Aurora, Colorado, USA; <sup>12</sup>Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA; <sup>13</sup>Department of Surgery, University of Washington, Seattle, Washington, USA; <sup>14</sup>BM Alden Research Laboratory, Santa Monica, California, USA; <sup>15</sup>Division of Infectious Diseases, Department of Medicine, Rush University Medical Center, Chicago, Illinois, USA; <sup>16</sup>Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; <sup>17</sup>Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA; <sup>18</sup>Division of Infectious Diseases and Microbiology, Department of Medicine, Hospital Universitario Virgen Macarena, University of Seville, Biomedicine Institute of Seville-Consejo Superior de Investigaciones Científicas, Seville, Spain; <sup>19</sup>Department of Surgery, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA; <sup>20</sup>Department of Medicine and Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; <sup>21</sup>Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA; and <sup>22</sup>Clinical Affairs and Practice Guidelines, Infectious Diseases Society of America, Arlington, Virginia, USA

As the first part of an update to the clinical practice guideline on the diagnosis and management of complicated intra-abdominal infections in adults, children, and pregnant people, developed by the Infectious Diseases Society of America, the panel presents 21 updated recommendations. These recommendations span risk assessment, diagnostic imaging, and microbiological evaluation. The panel's recommendations are based on evidence derived from systematic literature reviews and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

**Keywords.** intra-abdominal infection; guideline; risk assessment; diagnostic imaging; microbiological evaluation.

### BACKGROUND

A complicated intra-abdominal infection extends beyond the hollow viscus of origin into the peritoneal space or an otherwise sterile region of the abdominal cavity and is associated with peritonitis with or without abscess formation. This terminology is not meant to describe the infection's severity or anatomy. An uncomplicated intra-abdominal infection involves only intramural inflammation of the gastrointestinal tract without

extension into the peritoneal space and can progress to a complicated infection if not adequately treated.

Complicated intra-abdominal infection is a commonly encountered clinical situation, with appendicitis alone affecting ~670 000 patients per year worldwide [1]. Intra-abdominal infection is the second most common cause of infectious morbidity and mortality in the intensive care unit. The requirement for intervention in most cases and the controversies surrounding the choice and nature of surgical procedures performed add layers of complexity to the management of these infections.

### Guideline Scope

The scope of this guideline includes acute appendicitis, acute cholecystitis (both acalculous and calculous), acute cholangitis, acute diverticulitis, abdominal abscess, secondary bowel perforation, and acute necrotizing pancreatitis. Where relevant, available evidence for children, pregnant adults, and non-pregnant

Received 19 June 2024; editorial decision 21 June 2024; published online 5 July 2024  
Correspondence: R. A. Bonomo, Louis Stokes Cleveland VA Medical Center, 10701 East Blvd, Cleveland, OH 44106 (practicingguidelines@idsociety.org).

### Clinical Infectious Diseases®

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.  
<https://doi.org/10.1093/cid/ciae346>







# At the Forefront of Pandemic and Outbreak Response

Advising CDC, Federal Agencies,  
White House

Developing Rapid Guidelines

Broader Media Outreach





# Reflecting the Faces of ID

Inclusion, Diversity, Access & Equity  
Roadmap and Strategies

IDA&E Committee

Diverse Slate of Board Members



# 2025:

## Refreshed strategic plan





# **IDSA's New Strategic Priorities**

**1**

**Build and sustain a broad, diverse and valued ID workforce to improve patient care, advance science and promote public health**

**2**

**Promote IDSA as the leader and trusted source for timely, evidence-based infectious diseases content and expertise**

**3**

**Expand IDSA's leadership in preventing, preparing for and responding to infectious diseases threats to protect our communities**





# 2025-2030 IDSA Strategic Priorities

## **Strategic Priority 1: Build and sustain a broad, diverse and valued ID workforce to improve patient care, advance science and promote public health**

- Goal 1: Foster thriving careers for ID professionals
- Goal 2: Attract and inspire medical students, residents and fellows to pursue a rewarding career in ID
- Goal 3: Ensure the ID workforce is accessible to, and reflects the diversity of, the communities it serves



# 2025-2030 IDSA Strategic Priorities

**Strategic Priority 2: Promote IDSA as the leader and trusted source for timely, evidence-based infectious diseases content and expertise**

- Goal 1: Increase recognition of IDSA and the IDSA brand
- Goal 2: Expand the reach and impact of IDSA's products and services



# 2025-2030 IDSA Strategic Priorities

**Strategic Priority 3: Expand IDSA's leadership in preventing, preparing for and responding to infectious diseases threats to protect our communities**

- Goal 1: Reduce the impact of antimicrobial resistance
- Goal 2: Position the ID workforce for effective outbreak and pandemic preparedness and response







# Rebrand

**Revitalizing Our Brand, Reshaping Our Identity  
and Reinforcing Our Value**

**IDSA**  
Infectious Diseases Society of America



# Thank you



Web: [idsociety.org](http://idsociety.org)

Email: [info@idsociety.org](mailto:info@idsociety.org)

Phone: (703) 299-0200

